Quick Answer
EVO ICL (Implantable Collamer Lens) surgery is a refractive eye procedure in which a surgeon implants a thin, flexible lens between the iris and the natural crystalline lens of the eye. Unlike LASIK, no corneal tissue is removed. The lens corrects nearsightedness (myopia) ranging from -3D to -20D and astigmatism up to -4D. The procedure typically takes 20 to 30 minutes per eye and is fully reversible.
Detailed Explanation
EVO ICL is manufactured by STAAR Surgical and represents the latest generation of implantable collamer lens technology. The “EVO” designation refers to the evolved design that includes a central port — called KS-AquaPORT — which allows aqueous humor (the eye’s natural fluid) to flow without restriction. This eliminated the need for a preparatory laser iridotomy procedure that older ICL models required.
The lens itself is made from Collamer, a proprietary biocompatible material composed of collagen and a hydrophilic polymer. Because Collamer is biologically inert, the eye does not recognize the lens as a foreign object. The lens also contains a UV-blocking component, providing an added layer of ocular protection.
How the procedure works:
1. The surgeon applies topical anesthetic eye drops. General anesthesia is not required. 2. A micro-incision (approximately 3mm) is made at the edge of the cornea. 3. The folded EVO ICL lens is inserted through the incision using a specialized injector. 4. The lens unfolds and positions itself in the posterior chamber — the space between the iris and the natural lens. 5. The incision is self-sealing and typically requires no sutures.
The entire procedure per eye usually takes between 20 and 30 minutes. Most surgeons treat both eyes on the same day or on consecutive days.
Who benefits most from EVO ICL:
EVO ICL was designed specifically for patients who fall outside the safe treatment range for laser vision correction procedures like LASIK or PRK. It is particularly well-suited for individuals with:
- High myopia (stronger prescriptions than LASIK can safely treat)
- Thin corneas that disqualify them from laser surgery
- Dry eye conditions that make laser procedures inadvisable
- Prescriptions that have been stable for at least one year
The FDA approved EVO ICL in 2022 for adults between 21 and 45 years of age with myopia of -3D to -20D, with or without astigmatism up to -4D.
For a full overview of recognized surgeons and clinical standards in this specialty, visit the EVO ICL Awards page.
How EVO ICL differs from traditional contact lenses:
The EVO ICL is not a contact lens in any practical sense. Standard contacts sit on the surface of the eye and must be removed daily. The EVO ICL sits inside the eye, requires no maintenance, and is not felt or touched by the patient after placement. Vision correction is continuous and uninterrupted.
Clinical outcomes:
Clinical trials submitted to the FDA showed that 99.4% of patients achieved 20/40 or better uncorrected vision after EVO ICL implantation. Over 94% achieved 20/20 or better. Patient satisfaction rates in published studies consistently exceed 99%, making EVO ICL one of the highest-rated elective procedures in all of ophthalmology.
Important Considerations
Before pursuing EVO ICL surgery, patients and their physicians must evaluate several anatomical requirements. The anterior chamber depth (ACD) — the space between the cornea and the natural lens — must measure at least 3.0mm to accommodate the ICL safely. Insufficient ACD is one of the most common reasons patients are disqualified.
Patients with a history of certain conditions including glaucoma, iritis, or diabetic retinopathy are generally not candidates. A comprehensive preoperative examination — including corneal topography, pachymetry, and biometry — is required before any surgeon can confirm candidacy.
The lens comes in multiple sizes, and accurate sizing is critical. An improperly sized lens can cause elevated intraocular pressure (if too large) or suboptimal positioning (if too small). Surgeons use a combination of white-to-white measurements and anterior segment OCT imaging to determine the correct lens size.
Patients considering EVO ICL should also verify that their prescription has been stable — meaning less than 0.5D of change — for at least 12 months prior to surgery. A prescription that continues to evolve is a contraindication.
What to Do Next
If EVO ICL sounds like a potential fit, your next step is scheduling a candidacy evaluation with a qualified ophthalmologist who performs the procedure regularly. During this consultation, you should ask about their total EVO ICL case volume, their approach to lens sizing, and their outcomes data for patients with a prescription similar to yours.
Use the EVO ICL Awards directory to identify surgeons who have been recognized for clinical excellence in this specific procedure. Award recognition reflects peer evaluation, patient outcomes, and demonstrated expertise — not simply years in practice.
You should also review How Do I Find the Best EVO ICL Surgeon? for a structured framework to evaluate and compare providers before committing.
Related Questions
Can the lens be removed if something changes? Yes. EVO ICL is fully reversible. Read Can EVO ICL Be Removed? for details on what removal involves and when it might be necessary.
How does EVO ICL compare to LASIK? The two procedures take fundamentally different approaches. See Is EVO ICL Better Than LASIK? for a direct clinical comparison.
What are the risks? Like any surgical procedure, EVO ICL carries specific risk factors. Review What Are the Risks of EVO ICL Surgery? for a complete breakdown.